参考文献：[1]Kudo M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug;69(8):1492-1501.[2]Kudo M, et al. IMbrave150: Efficacy and Safety...
2.Wang K, Xiang Y J, Yu H M, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial[J]. Nature Medicine, 2024: 1-8. 3.M. Kudo , R. Lencioni ...
3.Wang K, Xiang Y J, Yu H M, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial[J]. Nature Medicine, 2024: 1-8. END
参考文献: [1]Kudo M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug;69(8):1492-1501. [2]Kudo M, et al. IMbrave150: Efficacy and Saf...
随后的CHANCE2201研究为比较TACE联合靶免(802例)对比单纯靶免(442例)在晚期HCC(BCLC C期/CNLC IIIa期)的有效性及安全性的RWS, 采用模拟目标试验框架(Target Trial Emulation Framework)分析。结果显示,TACE联合靶免治疗组中位OS及PFS分别为22.6个月及9.9个月,ORR为47.3%,均显著优于单纯靶免治疗组的15.9个月,...
EP: 14.CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape EP: 15.REGONEXT Study: Driving Second-line HCC Treatment Strategy EP: 16.Trajectory of Evolving HCC Treatment Landscape Newsletter Stay up to date on the most recent and practice-changing oncology data Subscrib...
Pts continue to be followed for OS.Conclusions:D+B+TACE is the first ICI-based regimen in a global Phase 3 trial to show statistically significant and clinically meaningful improvement in PFS, vs TACE, in pts with embolization-eligible uHCC. Safety was manageable and consistent with the safety...
随着生物科学技术的进步,各种类型创新疗法不断涌现并在临床研究得到验证,展现出了巨大的临床潜力。新技术、新靶点药物的早期临床研究与注册性临床研究(Pivotal Trial)的价值在整个药物研发中日益显著。其中,试验结果对于适应症拓展与后续研究的方案制定具有举足轻重的作用,因而对结果的解读很有必要。
EMERALD-2 (MORF-057-202)is a global phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 that is currently enrolling patients with moderate-to-severe ulcerative colitis. The primary endpoint of EMERALD-2 i...
This trial is designed from the outset to continuously and objectively track patients’ function and their potential change in response to treatment, without requiring them to wear sensors or alter their behavior,” said Dr. Dina Katabi, the President and co...